Medy-Tox메디톡스

Medy-Tox's profits have shrunk sharply from 2021-2022 levels, while the share price has fallen about 44% over the past year.

Medy-Tox, a botulinum toxin and filler maker, posted trailing twelve-month revenue of about ₩251B to H1 2026 and a net margin of 6.1%. The stock closed at ₩67,400 on 2026-10-23, near its 52-week low of ₩61,600 and well below its high of ₩141,100. The company is paying an interim cash dividend of ₩1,200 per share, with a 1.8% dividend yield.

What stands out

• Revenue grew 8.2% in 2025 to about ₩247B, but operating income was ₩17.0B, down from ₩46.7B in 2022 and ₩20.3B in 2024.
• Net income fell from ₩94.2B in 2021 to ₩16.6B in 2025, and trailing ROE is 3.6%.
• Trailing cash of ₩46.9B sits against borrowings of ₩122.6B, and liabilities are 50.8% of equity.
• Trailing free cash flow is about ₩54.4B, which is well above trailing net income of ₩15.3B.
• Foreign ownership fell from 15.9% to 12.2% over about 60 days, while retail and institutional investors were net sellers over the last 20 days.

What to watch

• The interim dividend record date and payment, following the October 2026 dividend decisions and amendments.
• The full-year 2026 results and any changes to the share cancellation plan mentioned in the filings.
• The stock's fall of about 44% over one year; the data does not explain the cause, so check the company's filings and news for details.
• The DCF fair value model gives a base of ₩34,651, below the current price; this is a model output, not a forecast, and the data contains no analyst targets.